Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.

Journal of Medicinal Chemistry
Huiyu RenNicholas D P Cosford

Abstract

Inhibition of autophagy, the major cellular recycling pathway in mammalian cells, is a promising strategy for the treatment of triple-negative breast cancer (TNBC). We previously reported SBI-0206965, a small molecule inhibitor of unc-51-like autophagy activating kinase 1 (ULK1), which is a key regulator of autophagy initiation. Herein, we describe the design, synthesis, and characterization of new dual inhibitors of ULK1 and ULK2 (ULK1/2). One inhibitor, SBP-7455 (compound 26), displayed improved binding affinity for ULK1/2 compared with SBI-0206965, potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice. SBP-7455 inhibited starvation-induced autophagic flux in TNBC cells that were dependent on autophagy for survival and displayed synergistic cytotoxicity with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib against TNBC cells. These data suggest that combining ULK1/2 and PARP inhibition may have clinical utility for the treatment of TNBC.

References

Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Pavol SkubákNavraj S Pannu
Jan 20, 2007·The Journal of Clinical Investigation·Ravi K AmaravadiCraig B Thompson
Mar 5, 2009·The Journal of Biological Chemistry·Ian G GanleyXuejun Jiang
Jul 15, 2009·Autophagy·Nao HosokawaNoboru Mizushima
Jan 29, 2010·Assay and Drug Development Technologies·Hicham ZegzoutiSaid A Goueli
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Wolfgang Kabsch
Mar 5, 2010·Nature Reviews. Cancer·Michèle RouleauGuy G Poirier
Jul 20, 2010·Biochimica Et Biophysica Acta·Suning ChenJian Zhang
Sep 3, 2010·Nature Cell Biology·Zhifen Yang, Daniel J Klionsky
Dec 15, 2010·Molecular Oncology·Aleix Prat, Charles M Perou
May 10, 2011·Annual Review of Biochemistry·Arvin C Dar, Kevan M Shokat
Oct 8, 2011·Genes & Development·Alec C Kimmelman
Apr 17, 2012·Cell·Mathieu Laplante, David M Sabatini
May 21, 2013·Nature Cell Biology·Ryan C RussellKun-Liang Guan
Jun 26, 2013·Acta Crystallographica. Section D, Biological Crystallography·Philip R Evans, Garib N Murshudov
Sep 26, 2013·Nature Reviews. Cancer·Caitriona HolohanPatrick G Johnston
Dec 7, 2013·Nature·Mathias T RosenfeldtKevin M Ryan
Dec 10, 2013·Cell·Jessie Yanxiang GuoEileen White
Jan 21, 2014·Molecular Cell·Daniel PapinskiClaudine Kraft
Jan 22, 2014·Nature Communications·Shuan RaoJosef M Penninger
Apr 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Suganthi ChittaranjanSharon M Gorski
Dec 7, 2014·Cell·Lorenzo GalluzziGuido Kroemer
Jan 1, 2015·ACS Chemical Biology·Michael B LazarusKevan M Shokat
Feb 6, 2015·The Journal of Clinical Investigation·Eileen White
Apr 22, 2015·Oncogene·V W Rebecca, R K Amaravadi
Nov 4, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Dec 4, 2015·Nature Communications·Matthew B RobersKeith V Wood
Dec 18, 2015·BBA Clinical·Elma A O'ReillyAmanda McCann
Feb 13, 2016·Annual Review of Biochemistry·Carla F BentoDavid C Rubinsztein
Mar 27, 2016·Science Signaling·Paulo Sérgio L de OliveiraDeborah Schechtman
Apr 10, 2016·Journal of Molecular Biology·Daniel Papinski, Claudine Kraft
May 7, 2016·Bioinformatics·Giovanni Y Di VeroliDuncan I Jodrell
Dec 10, 2016·Critical Reviews in Oncology/hematology·Amy DréanAlan Ashworth
Mar 16, 2017·Acta Crystallographica. Section D, Structural Biology·Paul Emsley
May 23, 2017·Nature Reviews. Drug Discovery·Lorenzo GalluzziGuido Kroemer
Jun 3, 2017·Methods in Molecular Biology·Airlie J McCoy
Aug 11, 2017·Genes & Development·Thomas J CunninghamAlexandre R Colas

❮ Previous
Next ❯

Citations

Jul 1, 2021·The Biochemical Journal·Sebastian MatheaStefan Knapp
Jul 29, 2021·Journal of Drug Targeting·Yingying LiGuangxi Zhai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autophagy Networks

Autophagy is a lysosomal pathway that involves degradation of proteins and functions in normal growth and pathological conditions, through a series of complex networks. The catabolic process involves delivery of proteins and organelles to the lysosome. Here is the latest research on autophagy networks.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Autophagosome

An autophagosome is the formation of double-membrane vesicles that involve numerous proteins and cytoplasmic components. These double-membrane vesicles are then terminated at the lysosome where they are degraded. Discover the latest research on autophagosomes here.

Autophagosome

An autophagosome is the formation of double-membrane vesicles that involve numerous proteins and cytoplasmic components. These double-membrane vesicles are then terminated at the lysosome where they are degraded. Discover the latest research on autophagosomes here.